Epizyme Updated Tazemetostat Phase 1 Data Show Clinical Activity in a Broader Range of Adults With INI1-Negative and SMARCA4-Negative Solid Tumors

Epizyme, Inc.

reported results today from the ongoing phase 1 trial of tazemetostat, its first-in-class EZH2 inhibitor. The data showed that tazemetostat demonstrated clinical activity in a broader group of patients with INI1-negative and SMARCA4-negative tumors than previously reported, achieved inhibition of EZH2 in tumor tissue, and had an acceptable safety profile when administered as oral monotherapy in adult patients with relapsed or refractory INI1-negative and SMARCA4-negative tumors. The data were presented at the European Cancer Congress 2015 (ECC) in Vienna, Austria by Antoine Italiano, M.D., Ph.D., of the Institut Bergonié in Bordeaux, France. Based on tazemetostat's clinical activity observed to date and other supportive research, Epizyme will initiate a global phase 2 study in